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Gene therapy for hematological disorders relies on the 
genetic modification of CD34+ cells, a heterogeneous 
cell population containing about 0.01% long-term 
repopulating cells. Here, we show that the lentiviral vec-
tor CD133-LV, which uses a surface marker on human 
primitive hematopoietic stem cells (HSCs) as entry recep-
tor, transfers genes preferentially into cells with high 
engraftment capability. Transduction of unstimulated 
CD34+ cells with CD133-LV resulted in gene marking 
of cells with competitive proliferative advantage in vitro 
and in immunodeficient mice. The CD133-LV- transduced 
population contained significantly more cells with repop-
ulating capacity than cells transduced with vesicular sto-
matitis virus (VSV)-LV, a lentiviral vector pseudotyped 
with the vesicular stomatitis virus G protein. Upon trans-
fer of a barcode library, CD133-LV-transduced cells sus-
tained gene marking in vivo for a prolonged period of 
time with a 6.7-fold higher recovery of barcodes com-
pared to transduced control cells. Moreover, CD133- 
LV-transduced cells were capable of repopulating second-
ary recipients. Lastly, we show that this targeting strategy 
can be used for transfer of a therapeutic gene into CD34+ 
cells obtained from patients suffering of X-linked chronic 
granulomatous disease. In conclusion, direct gene trans-
fer into CD133+ cells allows for sustained long-term 
engraftment of gene corrected cells.
Received 5 June 2014; accepted 25 August 2014; advance online  
publication 14 October 2014. doi:10.1038/mt.2014.173
INTRODUCTION
A series of phase 1/2 clinical trials have provided convinc-
ing evidence that correction of genetic defects by ex vivo gene 
transfer into hematopoietic CD34+ cells is an alternative thera-
peutic approach to allogeneic hematopoietic stem cell trans-
plantation (HSCT), in particular for patients lacking a suitable 
matched donor.1–5 Usually, CD34+ cells from granulocyte colony-
stimulating factor (GCSF)-mobilized peripheral blood (mPB) are 
genetically modified in this approach. This cell population is het-
erogeneous and contains, in addition to a few cells with long-term 
repopulating capability (~0.01%),6 a vast excess of multilineage 
progenitors with short-term engraftment properties as well as 
more differentiated lineage-restricted progenitors with low or no 
engraftment capabilities.7–9 The relevant target cell for sustained 
gene correction is the primitive hematopoietic stem cell (HSC) 
with long-term repopulating and self-renewal capacity (LT-HSC).
A series of elegant studies have characterized LT-HSC based 
on their multilineage repopulating capacity in nonobese diabetic/
severe combined immunodeficient (NOD/SCID) mice.10,11 This 
SCID-repopulating cell (SRC) is exclusively contained within the 
CD34+CD38− fraction of human bone marrow, cord blood, and 
mobilized peripheral blood (mPB) cells.7,12 In addition, expres-
sion of CD133 (prominin-1) correlates with the capacity of the 
cells to engraft long-term, thereby defining CD133 as an addi-
tional cell surface marker of LT-HSCs. 13,14 Hematopoietic cells 
isolated on the basis of CD133 expression possess a higher con-
tent of long-term culture initiating cells (LTC-IC) and increased 
proliferative capacity in vitro than cells isolated on CD34 expres-
sion.15,16 Coexpression of CD34 and CD133 is highest in samples 
from mPB reaching up to 80% compared to CB (50%) and BM 
(13%), and most of the SRC activity is contained within this cell 
population.17,18 First clinical trials have shown that cells isolated 
for CD133+ expression can substitute for standard CD34+ cells in 
HSC transplantation.19
Thus, one alternative to direct gene transfer to LT-HSCs 
is to enrich for primitive HSCs based on cell surface marker 
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expression before transduction. Indeed, lentiviral transduction of 
mPB CD34+CD38−Lin− cells resulted in high gene transfer effi-
ciencies and stable gene marking of LTC-IC and colony-forming 
cells derived thereof for more than 10 weeks in liquid cultures.20 
However, bystander cells are beneficial for accelerated hematopoi-
etic reconstitution after full myeloablative conditioning and thus 
isolation and transplantation of pure LT-HSCs might be disadvan-
tageous.21 Hence, an ideal approach for gene therapy directs gene 
transfer to the LT-HSC population present within the heteroge-
neous pool of CD34+ cells.
The most widely used envelope for pseudotyping lentiviral 
vectors (LVs) is the vesicular stomatitis virus (VSV) glycoprotein 
G. The LDL receptor family members were recently identified as 
entry receptors for VSV-LV particles.22 Therefore, VSV-G pseudo-
typed vectors have the capacity to transduce a wide range of cell 
types and have been successfully used for the genetic modification 
of cells in the context of gene therapy trials (reviewed in ref. 5).
A strictly defined tropism can be achieved by the versatile tar-
geting strategy relying on the two measles virus envelope proteins: 
the hemagglutinin (H) mediates receptor attachment while the 
fusion protein (F) is responsible for vector particle cell membrane 
fusion. Upon blinding the H protein for recognition of its natu-
ral receptors23,24 and linking it to a single-chain antibody (scFv) 
recognizing the cell surface antigen of choice, receptor-targeted 
vectors highly specific for a variety of cell types have been gener-
ated.25,26 Among these, CD133-LV, which displays a scFv derived 
from the CD133-specific monoclonal antibody 141.7, efficiently 
targets CD133+ cells in mPB cells.25
Here, we show that CD133-LV preferentially transduces a 
population of human hematopoietic stem cells with high prolif-
erative potential in vitro and multilineage engraftment in vivo, 
highlighting the potential of CD133-LVs as an alternative to 
 VSV-pseudotyped lentiviral vectors for gene therapy of hemato-
logical disorders.
RESULTS
Targeted gene transfer into human CD133hi/CD34hi/
CD38− cells
To identify the target cell population of CD133-LV, we first ana-
lyzed mPB CD34+ cells for coexpression of CD133 and CD38 
(Figure 1a). Next, we sorted CD34+ cells into discrete popula-
tions of cells expressing high or low CD34 or CD38, while for 
CD133+ an additional population with intermediate mean fluo-
rescence intensity was isolated (Figure 1b). These cell popula-
tions were individually transduced with CD133-LV or lentiviral 
vector pseudotyped with the VSV-G envelope protein (VSV-LV). 
Transductions were performed at low multiplicity of infection and 
in the absence of cytokine prestimulation, as the CD133 marker is 
rapidly downregulated upon cultivation of freshly isolated CD34+ 
cells in the presence of cytokines (Supplementary Figure S1). 
Under these conditions, transduction efficiencies were rather low 
(~10%), but high enough to identify the transduced cell types. 
CD133-LV preferentially transduced CD133hi, CD34hi, and CD38lo 
but also CD133mid, CD34lo, CD38hi, and CD133lo cells, albeit at a 
markedly reduced efficiency (Figure 1c). In contrast, this more 
mature cell population was preferentially transduced by VSV-LV, 
while the CD133hi, CD38lo, and CD34hi populations were barely 
transduced under the conditions used in these experiments. From 
these observations, we conclude that CD133-LV transduces pref-
erentially CD133bright cells, which in addition are positive for CD34 
and negative for CD38, a human hematopoietic cell population 
with phenotypic characteristics attributed to stem cells.
CD133-LV transduces a cell population with high 
proliferative potential
Freshly isolated mPB CD34+ cells were transduced overnight with 
CD133-LV and VSV-LV, expressing tuBFP and eGFP, respectively 
(Figure 2a). Transduction efficiencies ranged from 2% up to 20% 
for CD133-LV(tuBFP) and 5–40% for VSV-LV(GFP). To avoid 
skewing of the results due to pseudotransduction, events with 
low fluorescence intensity were excluded at early time points by 
stringent gating. Transduced cells were kept in culture for 17 days 
under cytokine stimulation to assess their proliferative potential. 
While CD133-LV-transduced cells continuously expanded dur-
ing culture, the proportion of VSV-LV transduced cells declined 
gradually from initially 17–10% (Figure 2b,c). Thus, CD133-LV 
transduces a cell population with extensive proliferative capac-
ity, a hallmark of hematopoietic stem and primitive progenitor 
cells.7 This effect was also observed when cells were prestimu-
lated for 12, 24, or 36 hours prior to transduction. Although 
Figure 1 Targeted gene transfer into human CD133hi/CD34hi/CD38low 
cells. (a) Correlation of CD133 expression with established  hematopoietic 
stem cell (HSC) markers in freshly isolated mPB CD34+ cells (purity >95%). 
(b) Sorting of mPB CD34+ cells into discrete subpopulations according to 
the expression intensities of CD34, CD38, and CD133. For CD34 and 
CD38, the highest and lowest 15% of cells were isolated via FACS; for 
CD133 expression, cells were subdivided into three intervals (lowest, 
mid, highest), each 30% of the total population. (c) Sorted cells obtained 
from b were cultured at identical conditions and transduced with equal 
amounts of transducing units of VSV- or CD133-LV to estimate the relative 
transduction efficiency on different hematopoietic stem-progenitor cells 
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overall transduction efficiencies for CD133-LV decreased with 
extended prestimulation time, the overall dynamics of transduced 
cell  fractions remained surprisingly consistent (Supplementary 
Figure S2). In contrast, transduction of CD34+ cells with  VSV-LVs 
resulted in increased transduction efficiencies with increased pre-
stimulation time. However, gene marking was not sustained over 
time. These observations confirm preferential transduction by 
CD133-LV of cells with high proliferative potential.
In order to maintain the HSC phenotype and to support opti-
mal transduction conditions for CD133-LV, subsequent experi-
ments were performed in the absence of prestimulation.
Preferential competitive engraftment of CD133- 
LV-transduced human cells in NSG mice
As human HSCs are functionally best defined by their property to 
engraft into NSG animals, we performed a competitive repopula-
tion assay in vivo with CD133-LV and VSV-LV transduced cells. 
Mobilized PB CD34+ cells were transduced with color-coded len-
tiviral vectors, mixed at a cell ratio of 1:1 and transplanted at a 
total cell dose of 5 × 105 or 1 × 106 cells into NSG animals. Initial 
transduction efficiencies ranged from 2 to 20% for CD133-LV and 
VSV-LV. Bone marrow, spleen, and thymus of transplanted animals 
were analyzed for human engraftment (huCD45+) in the myeloid 
and lymphoid compartment at weeks 8, 12, and 16 post-transplan-
tation according to the gating strategy shown in Figure  3a. We 
found high and sustained engraftment levels in transplanted ani-
mals, likely resulting from the short one day ex vivo culture used 
in our experimental procedure (Supplementary Figure S3a). 
Analysis of bone marrow, spleen, and thymus of transplanted 
animals at week 16 post-transplantation revealed that the most 
prominent gene-marked cell population engrafted in bone mar-
row and spleen were derived from CD133-LV transduced cells, 
while no significant difference between groups was observed in 
the thymus (Figure 3b). These findings were also reflected by the 
main hematopoietic cell subsets present in the different organs. 
We found a clear dominance of CD133-LV-transduced myeloid 
and B cells in bone marrow and spleen, while the contribution of 
either CD133-LV- or VSV-LV-transduced cells to the CD3 T-cell 
Figure 2 In vitro competitive proliferation kinetics of mPB CD34+ cells 
transduced with VSV-LV and CD133-LV. (a) Lentiviral vectors encod-
ing green or blue fluorescent proteins were packaged using VSV-G or 
CD133-targeting envelopes, respectively. Subsequently freshly isolated 
mPB CD34+ cells were transduced using both vectors and cultivated for 
up to 17 days in vitro in cytokine-supplemented media. (b) The fraction of 
transduced cells was analyzed in regular intervals by flow cytometry. (c) 
The average fold change of percentage transduced cells from six indepen-
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Figure 3 Competitive repopulation assays of gene modified hCD34+ cells in NSG mice. (a) Representative gating scheme used for the iden-
tification of transduced cells within human derived myeloid, B- and T-cell populations. (b) Representation of all transplanted animals as described 
in Supplementary Information on a log2 scale. Total hCD45+ cells from the bone marrow (BM, n = 53), spleen (n = 45), or thymus (n = 19) 
are shown. A value of zero indicates a constant ratio of CD133-LV versus VSV-LV gene modified cells, above zero indicates superior performance of 
CD133-LV transduced cells. (c) Same analysis as in b, but subdivided into myeloid, B- and T-cells to reveal a possible lineage preference of cells trans-
duced with either VSV- or CD133-LVs. eF780: Viability dye, *, **, and *** correspond to P ≤ 0.05, 0.01, or 0.001 respectively. Fold change is given as 
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compartment in spleen and thymus was more balanced (Figure 3c 
and Supplementary Figure S3b). This likely resulted from differ-
ent repopulation kinetics of T cells compared to myeloid and B 
cells. The superior competitive repopulation potential of CD133-
LV-transduced cells was stable throughout week 8, 12, and 16 
post-transplantation, indicating that this effect is established 
within the first 8 weeks after transplantation and remains constant 
thereafter (Supplementary Figure S3c).
The observed differences in the repopulation capacity of 
CD133-LV- and VSV-LV-transduced cells could be simply 
explained from toxic effects of the VSV-LV vector prepara-
tion, resulting in the ablation of engrafting cells in the VSV-LV-
transduced population. Therefore, we cultured hCD34+ cells 
with increasing amounts of either CD133-LV or VSV-LV. The 
percentage of 7AAD+/AnnexinV+ cells was measured 2 days 
after transduction. No significant differences in cell toxicity were 
observed between both vector preparations. At the dilutions used 
for transduction of hCD34+ cells (1% for VSV-LV and 10% for 
CD133-LV), the CD133-LV supernatant was more toxic than the 
VSV-LV vector preparation (Supplementary Figure S4).
Next, we performed secondary transplantation to confirm the 
stem cell character of transduced cells. In analogy to the previ-
ous experiment, primary animals were transplanted with a 1:1 
mixture of CD133- and VSV-LV-transduced cells together with 
a 15-fold excess of unmodified cells. Animals were analyzed 
for myeloid and lymphoid engraftment in the bone marrow at 
week 12 post-transplantation (Figure 4a). In agreement with the 
results shown in Figure 3b,c, the myeloid and B-cell compart-
ment contained substantially more CD133-LV-transduced cells 
than  VSV-LV-transduced cells, while contribution to the CD3+ 
population was similar (Figure 4a). Human CD34+ cells were iso-
lated from the bone marrow of primary transplanted animals and 
retransplanted into secondary NSG mice. At this time point, gene 
marked hCD34+ cells were predominantly derived from CD133- 
LV-transduced cells (Figure 4b). Secondary animals were ana-
lyzed 12 weeks after transplantation for myeloid and lymphoid 
engraftment in bone marrow and spleen. While most of the ani-
mals (63–88%) engrafted with CD133-LV-derived cells, only a 
few of the secondary animals showed engraftment of VSV-LV-
transduced cells (13% in the bone marrow, 0% in the spleen) 
(Figure 4b). Thus, this result confirms that CD133-LV-derived 
vectors transduced a cell population with long-term multilin-
eage repopulation capabilities in primary and secondary animals 
under competitive conditions.
Higher frequency of repopulating HSCs with 
multilineage contribution within the CD133-LV-
transduced cell population
The SRC frequency within the transduced cell fraction was deter-
mined in competitive repopulation experiments using limiting dilu-
tions of CD133-LV- and VSV-LV-transduced cells. NSG mice were 
transplanted with a total of 1 × 106 cells or serial dilutions thereof 
containing a 1:1 cell ratio of CD133-LV- and VSV-LV-transduced 
hCD34+ cells. After correction for transduction efficiency (20% 
for VSV-LV and 5% for CD133-LV), the high-dose cohort was 
transplanted with 2.4 × 104 CD133-LV and 9.9 × 104 VSV-LV-
transduced cells together with 8.8 × 105 nontransduced competi-
tor cells. We analyzed the mice 16 weeks after transplantation for 
Figure 4 Competitive serial transplantation assay. (a) Primary mice were transplanted with indicated numbers of gene modified cells along with a 
15-fold excess of unmodified cells. See legend to Figure 3 for further information. (b) Twelve weeks later, hCD34+ cells were isolated from the bone 
marrow of 12 mice and transferred into 8 secondary recipient mice for further 12 weeks. The table indicates the frequency of mice in which VSV-LV 
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contribution of gene marked cells to the total CD45+ cell popu-
lation (cutoff: 0.1%). From this analysis, the frequency of SRCs 
in the CD133-LV-transduced population was 1 in 12,547 (95% 
confidence interval (CI): 7,055–22,316), while this number was 
1 in 55,136 for VSV-LV-transduced cells (95% CI: 30,805–98,683) 
(Figure 5a and Supplementary Table S1).
We also analyzed the frequency of engrafting cells within the 
CD133-LV- and VSV-LV-transduced population using DNA bar-
coded CD133-LV and VSV-LV vector libraries as unique identi-
fier for individual transduced cells. Deep sequencing was used 
to determine the identity of bar-codes in isolated hCD45+ cells 
16 weeks after transplantation. The sum of barcodes determined 
in all mice in the experimental group totaled 338 and 1,218 in 
the CD133-LV- and VSV-LV-transplanted groups, respectively 
(nine mice per group). After correcting for the total input of gene 
marked cells per animal (845 and 20,685 for CD133-LV- and VSV-
LV-transduced cells, respectively), we found in average a 6.7-fold 
difference in the recovery of DNA barcodes for CD133-LV- versus 
VSV-LV-transduced cells (Figure 5b). Taken together, our data 
suggest that the CD133-LV targets gene transfer to a more primi-
tive HSC fraction with increased long-term engraftment potential 
than vectors pseudotyped with VSV-G.
Lastly, we asked whether the CD133-targeting strategy would 
be applicable for the transfer of therapeutic genes into primitive 
repopulating cells. For this we used mPB CD34+ cells derived 
from a patient suffering from the X-linked form of chronic granu-
lomatous disease (X-CGD), a primary immunodeficiency charac-
terized by a defective elimination of microbes by phagocytic cells. 
In this case, frozen X-CGD CD34+ cells were used and allowed 
to recover for 24 hours prior to transduction. The proportion of 
CD34+ CD38− cells, which contains most of the CD133+ cells 
(see Figure 1a), after thawing and culture was 5%. Cells were 
transduced with CD133-LV expressing gp91phox from an internal 
viral promoter. One million cells per mouse were infused and the 
bone marrow was harvested 10 weeks after transplantation and 
analyzed for gp91phox expression in the human CD45 cell frac-
tion. As shown in Figure 5c, a clear gp91phox signal was observed 
in the human cell fraction, representing 14–18% of the gp91phox 
Figure 5 Preferential transduction of primitive hematopoietic stem cells (HSCs) by CD133-LV. (a) A limiting dilution competitive repopulation 
experiment was performed by cotransplantion of serial dilutions of limited numbers of CD133-LV- and VSV-LV-transduced cells. A total of 27 mice 
were transplanted in four dose groups. The frequency of repopulating HSCs in the total transduced graft was calculated using ELDA software based on 
a threshold of 0.1% of total CD45+ cells (mouse or human). (b) CD34+ cells from mobilized peripheral blood were transduced with barcoded VSV- or 
CD133-LV vectors. After 16 weeks, CD45-positive bone marrow cells were used to measure the clonal repertoire after high-throughput sequencing. 
The total number of different clones recovered in vivo is shown in relation to the number of initially injected barcoded clones and expressed as the 
percentage recovered clones. (c) XCGD derived BM CD34+ cells were transduced with CD133-LV expressing the gp91-transgene under control of a 
strong viral promoter. Cells were transplanted into NSG mice along with a control mouse which received identically treated mPB CD34 cells from a 
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expression recovered from the BM of animals transplanted with 
CD34+ cells derived from healthy donors.
DISCUSSION
Lentiviral vectors equipped with the VSV-G envelope protein 
have a proven record of being beneficial for patients suffering 
from genetic diseases that can be treated by HSC-based gene ther-
apy.1–3 While this clearly demonstrates that VSV-LV transduces 
long-term repopulating HSCs, its broad tropism supports gene 
transfer into all cell types present within the CD34+ cell popu-
lation making a high vector dose necessary to achieve sufficient 
transduction of the minor fraction of LT-HSC present within 
the CD34+ cell population.20,27–29 VSV-G protein recognizes the 
ubiquitously expressed LDL receptor (LDL-R) family as cellu-
lar entry port, explaining its broad cell tropism.22 The LDL-R is 
poorly expressed in quiescent T, B, and hematopoietic stem cells 
but increases after cytokine stimulation, making prestimulation of 
these cells prior to VSV-LV-mediated gene transfer necessary in 
order to achieve high transduction efficiencies.30–32 However, qui-
escent HSCs have a higher long-term engraftment capacity than 
cytokine-stimulated HSCs.33–35 The activation of CD34+ cells dur-
ing ex vivo culture therefore reduces the proportion of target cells 
with long-term repopulating capacity further.
Here, we provide evidence that these limitations can be over-
come by targeting LVs to CD133+ cells. CD133-targeted gene 
transfer into human hematopoietic long-term repopulating cells 
improves engraftment and multilineage repopulation while at the 
same time reduces vector dose, thereby potentially lowering the 
risk of insertional mutagenesis. Previous work aiming at improved 
rates of genetic modification of engrafting HSCs included optimi-
zation of ex vivo culture and transduction conditions as well as 
the use of envelope proteins derived from diverse viruses to pseu-
dotype lentiviral vectors. For example, lentiviral vectors pseudo-
typed with a chimeric envelope containing the extracellular and 
transmembrane domains of the feline leukemia virus RD114 
(RD114tr) or the prototype foamy virus envelope (PFVenv) have 
been reported to transduce HSC with high efficiency and to be 
less toxic than VSV-G.36–38 Nonetheless, these pseudotypes still 
possess a broad tropism and require an excess of vector particles. 
Preferential genetic modification of human CD34+ cells has also 
been achieved using envelopes containing membrane bound 
“early acting” cytokines, which have the capacity to activate qui-
escent HSC thereby facilitating gene transfer into these cells at 
low multiplicity of infection and even allow for in vivo gene trans-
fer.39,40 However, neither for this vector type nor for the pseudo-
types mentioned above, a side by side comparison with state of the 
art vector technology for the transduction of LT-HSCs has been 
provided. Considering the high variability in mouse repopulation 
assays only a competitive approach, in which both vector types are 
applied to the same donor cells, cultivated under the same condi-
tions, and, more importantly, implanted into the same individual 
mouse, will allow reliable conclusions.
We have used the CD133 antigen to target gene transfer pref-
erentially to a subset of CD34+ cells. Compared to CD34+ cells, 
CD133+ cells have a higher proliferative capacity in vitro, three-
fold higher LTC-IC and higher G0-content and most of the SRC 
activity.16,41,42 Although there is a substantial overlap between the 
expression of CD34 and CD133, CD133+/CD34− cells can gener-
ate CD133+/CD34+ cells, suggesting that the CD133+ cells com-
prise a more primitive cell type than the CD34+ fraction.43
Consistent with this, we found a 3.5-fold higher prolifera-
tion of CD133-LV- compared to VSV-LV-transduced cells dur-
ing 17 days of culture (Figure 2). This difference was even more 
pronounced when cells were transplanted into NSG mice. Then, 
CD133-LV was 4.8-fold more effective in the transduction of 
cell with competitive repopulation capacity (Figures 3b and 5a). 
Moreover, CD133-LV-derived cells engrafted secondary recipi-
ents with high efficiency, further supporting the primitive nature 
of CD133-LV-transduced cells (Figure 4). It is worth mentioning 
that also VSV-LV is capable of transducing serially transplantable 
HSCs when used at higher multiplicity of infection and under 
conditions optimized for VSV-mediated gene transfer, which 
routinely includes cytokine prestimulation. Lastly, the superior 
recovery rate of barcoded CD133-LV sequences over VSV-LV 
sequences from animals 16 weeks after transplantation (6.7-fold 
difference) provides clear evidence for the prolonged persistence 
of CD133-LV marked cells in vivo (Figure 5b).
The transduction conditions applied in our experiments dis-
favored gene transfer by VSV-LV, as no cytokine stimulation and 
low multiplicity of infections have been used.28,30 These condi-
tions ensured the presence of as many as possible CD133+ cells 
after isolation, since CD133 expression is rapidly downregu-
lated after cytokine stimulation and hematopoietic differentia-
tion (Supplementary Figure S1 and refs. 13,14). However, we also 
confirmed superior transduction of cells with high proliferative 
capacity in ex vivo culture by CD133-LV when prestimulation of 
up to 36 hours was used (Supplementary Figure S2).
Our data suggest, that directly isolating CD133+ cells and 
transducing with VSV-LV may represent a valid alternative pro-
cedure, although CD133-LV mediated gene transfer can be easily 
implemented into the well-established clinical protocols based on 
CD34 enrichment. Furthermore, there is a considerable heteroge-
neity within the CD133-positive fraction of HSCs both in terms 
of functionality and CD133 expression levels. We have previously 
demonstrated that entry targeted LVs preferentially transduce 
cells that express the highest levels of the targeted cell surface 
receptor.25,44 This holds true also for CD133-LV (Figure 1). Thus, 
even when transducing CD133-purified cells, CD133-LV will 
be advantageous as it preferentially modifies those cells express-
ing high levels of CD133, which are particularly enriched for 
CD38-negative cells and correlate with high expression of CD34 
(Figure 1). The more committed CD34low/CD38high/CD133low pro-
genitor pool is also transduced by CD133-LV, albeit to a lower 
degree, which might facilitate fast hematopoietic recovery upon 
conditioning and transplantation of gene modified cells.
Under the conditions used in our experiments about 10% 
of the CD34highCD133high cells were transduced. This is at least 
partly due to the moderate titers of CD133-LV vector superna-
tants, which were 1–2 log below the titers routinely obtained 
with VSV-LV.25 Higher transduction rates may also be pre-
vented by CD133-containing membrane vesicles which become 
released during differentiation of HSCs and potentially sequester 
CD133-LV particles.45 Removing these vesicles may thus fur-
ther enhance the transduction of repopulating cells in future. 
68 www.moleculartherapy.org vol. 23 no. 1 jan. 2015
© The American Society of Gene & Cell Therapy
Targeted Gene Transfer Into HSCs
Nevertheless, the moderate transduction efficiencies achieved so 
far were compensated by the high proliferative potential of the 
transduced CD133+ cells and by their capacity to engraft long-
term. Indeed, most of the animals transplanted with CD133- 
LV-modified cells engrafted. Thus, it appears that a few gene mod-
ified CD133+ cells may be sufficient to regenerate all hematopoi-
etic lineages with gene modified cells after transplantation into 
myeloablated recipients.
Besides HSCs, CD133 is also present in endothelial and 
neural progenitor cells and other progenitor cells derived from 
somatic tissues like prostate, liver, skin, and retina46,47 and in a 
variety of cancer stem cells, including acute and chronic myeloid 
and lymphoblastic leukemia, glioblastoma, and colon cancer.48 
Thus, CD133-LV may have a wider application beyond gene 
transfer into HSCs. Even an in vivo application of CD133-LV 
is conceivable in the near future. Although a humoral immune 
response may preclude the use of wild-type measles envelope 
in vivo as most of the human population is vaccinated against 
measles, immune escape mutants exists and can be used to pseu-
dotype gene transfer vectors.49–51 Thus, further improvements 
of the CD133 targeting strategy are feasible and may generate 
an extremely useful tool to direct gene transfer to normal and 
malignant stem and progenitor cells.
MATERIALS AND METHODS
Healthy donor human CD34+ cells from mobilized peripheral blood 
were isolated from mononuclear cell concentrates after written informed 
consent was obtained from donors according to the declaration of 
Helsinki. All procedures involving human samples were approved by 
the Institutional Ethics Committee. CD34+ cells were isolated using 
the CD34-microbead kit from Miltenyi, Bergisch-Gladbach, Germany 
according to the manufacturer’s instructions. After isolation, cells were 
cultured at a density of 106 cells/ml in SpemSpan SFEM supplemented 
with human stem cell factor (50 ng/ml), human thrombopoietin (10 ng/
ml), hIGFBP2 (100 ng/ml), and hFLT3L (50 ng/ml) and immediately 
transduced. Vector doses were adjusted to achieve similar transduction 
efficiencies in both VSV- and CD133-LV groups. After transduction cells 
were kept in culture for 17 days at a density of 0.2 to 1 × 106 cells/ml.
Animal experiments were performed in accordance with the German 
animal welfare legislation and were approved by the local authorities. 
Details on vector production, transplantations, flow cytometry, and 
sequence analysis of barcoded libraries are given in Supplementary Data.
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